<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Occupational asthma: prevention, identification &amp;amp; management: systematic review &amp;amp; recommendations.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Nicholson PJ, Cullinan P, Burge PS, Boyle C. Occupational asthma: prevention, identification &amp; management: systematic review &amp; recommendations. London (UK): British Occupational Health Research Foundation; 2010. 83 p.  [282 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: British Occupational Health Research Foundation (BOHRF). Guidelines for the prevention, identification and management of occupational asthma: evidence review and recommendations. London (UK): British Occupational Health Research Foundation (BOHRF); 2004. 88 p.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Allergic rhinitis, cause unspecified  (477.9); Asthma, unspecified type, unspecified  (493.90)"/><FieldValue Value="MSH: Asthma ; Asthma, Occupational ; Conjunctivitis, Allergic ; Guideline Adherence ; Guidelines as Topic ; Medical History Taking ; Occupational Diseases ; Occupational Exposure ; Occupational Health ; Occupational Health Services ; Occupational Medicine ; Peak Expiratory Flow Rate ; Prejudice ; Referral and Consultation ; Respiratory Protective Devices ; Rhinitis, Allergic ; Rhinitis, Allergic, Perennial ; Risk Assessment ; Risk Factors ; Risk Reduction Behavior ; Safety ; Sentinel Surveillance ; Serologic Tests ; Skin Tests "/><FieldValue Value="MTH: Allergic Conjunctivitis ; Allergic rhinitis (disorder) ; Asthma ; Asthma, unspecified type, without mention of status asthmaticus ; Guidelines ; Hypersensitivity skin testing ; occupational health specialty ; occupational medicine field ; Peak expiratory flow rate measurement ; Peak flow meter (device) ; Rhinitis, Allergic, Perennial ; Risk Assessment ; risk factors ; Safety ; Serologic tests "/><FieldValue Value="SNOMEDCT_US: Allergic conjunctivitis  (231854006); Allergic conjunctivitis  (473460002); Allergic rhinitis  (61582004); Asthma  (195967001); Asthma management  (406162001); Hypersensitivity skin testing  (164838003); Hypersensitivity skin testing  (268377001); Hypersensitivity skin testing  (53309004); Occupational asthma  (57607007); Occupational disorder  (115966001); Occupational health service  (2471000175109); Occupational health service  (310064001); Occupational medicine  (394821009); Peak flow meter  (334990001); Perennial allergic rhinitis  (446096008); Prejudice  (6811007); Risk assessment  (225338004); Risk factor  (80943009); Serologic test  (68793005)"/><FieldValue Value="SPN: METER, PEAK FLOW, SPIROMETRY "/><FieldValue Value="UMD: Flowmeters, Gas, Respiratory, Peak Expiratory Flow  (15-965)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Occupational asthma&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: The guidelines do not discuss non-occupational asthma except insofar as reviewing the evidence as to whether preexisting disease is a risk factor for developing occupational asthma.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Prevention" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Screening" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Allergy and Immunology" /><FieldValue Value="Family Practice" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Preventive Medicine" /><FieldValue Value="Pulmonary Medicine" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Nurses" /><FieldValue Value="Other" /><FieldValue Value="Patients" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /><FieldValue Value="Respiratory Care Practitioners" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To help reduce the incidence of occupational asthma by improved prevention and the severity of individual cases of disease by earlier identification and better management &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To provide managers, workers and safety and health professionals with evidence based guidance related to the prevention, identification and management of cases &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To update the first edition of these guidelines which reviewed the evidence published up to the end of June 2004 &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Workers with or at risk of occupational asthma&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;For Employers and Health and Safety Personnel&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Removing or reducing causes of occupational asthma from the work environment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ensuring that appropriate respiratory protective equipment is worn &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Informing workers about causes of occupational asthma and the need to report any relevant symptoms as soon as they develop &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Providing health surveillance of at-risk workers at least annually &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;For Health Practitioners&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Avoiding excluding individuals from employment due to poorly discriminating factors such as atopy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Enquiring about pre-existing occupational asthma &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Providing more frequent health surveillance to workers who develop rhinitis when working with agents known to cause occupational asthma and to workers with pre-existing asthma &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Enquiring of symptomatic individuals whether their symptoms improve when away from work &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Confirming a diagnosis of occupational asthma by objective criteria (functional, immunological, or both) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Performing serial peak flow measurements on workers suspected of having occupational asthma &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Performing skin prick or serological tests as part of the health surveillance &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Referral of workers to a physician with expertise in occupational asthma &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Following published clinical guidelines for the pharmacological management of patients with asthma &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;For Employers, Health and Safety Personnel and Health Practitioners&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Protecting workers diagnosed as having occupational asthma from further exposure to its cause in the workplace&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Sensitivity, specificity and accuracy of diagnostic measures &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Incidence of occupational asthma &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Average time between the onset of symptoms and the diagnosis of occupational asthma &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Effectiveness of treatment &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Systematic Literature Search&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Scientific Secretary performed the literature search of MEDLINE and EMBASE from 1966 and 1974 respectively for original scientific studies. For the first edition of the guidelines the literature was searched to the end of June 2004 using the search terms &quot;occupational asthma&quot; and &quot;asthmagens&quot; and relating to agents known to cause occupational asthma. For the 2010 evidence review the exercise was repeated for articles published from 2004 to the end of September 2009. The literature was searched using the search term &quot;occupational asthma&quot; for relevant articles published in English. The terms &quot;work&quot; AND &quot;asthma&quot; were avoided since experience from the first review confirmed that this was too sensitive and produced numerous irrelevant papers. More evidence emerged since the 2004 review relating to induced sputum and exhaled nitric oxide. The scope of the review was extended to include these investigations in the 2010 review and an additional specific search for relevant papers was performed retrospectively to 1966 for MEDLINE and 1974 for EMBASE.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Review of Abstracts&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;At each review the Scientific Secretary sent abstracts to paired members of the Research Working Group for independent double-blind selection of studies that were thought to merit critical appraisal. Case reports were excluded, as were narrative reviews, except for citation tracking. The Scientific Secretary informed reviewers of the results of the double-blind screening. Reviewers discussed differences and agreed upon full papers to be requested for review, or a third reviewer was used where it was essential to expedite the process.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A total of 223 papers contributing to the evidence were included for the previous version of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Additional 90 studies were included for the current update.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Scottish Intercollegiate Guidelines Network (SIGN) Levels of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Scottish Intercollegiate Guidelines Network (SIGN) Levels of Evidence&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;1++ &lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High quality meta analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a very low risk of bias&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;1+&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Well conducted meta analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a low risk of bias&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;1-&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Meta analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a high risk of bias&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;2++&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High quality systematic reviews of case-control or cohort studies. High quality case-control or cohort studies with a very low risk of confounding, bias, or chance and a high probability that the relationship is causal&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;2+&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Well conducted case control or cohort studies with a low risk of confounding, bias, or chance and a moderate probability that the relationship is causal&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;2-&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Case control or cohort studies with a high risk of confounding, bias, or chance and a significant risk that the relationship is not causal&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;3&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Non-analytic studies, e.g., case reports, case series&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;4&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Expert opinion&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Royal College of General Practitioners (RCGP) 3 Star System&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;(High quality scientific studies were taken to be major epidemiological surveys and prospective cohort studies. Medium quality studies included retrospective, cross-sectional or uncontrolled cohort studies and case series.)&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Scottish Royal College of General Practitioners (RCGP) 3 Star System&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; colspan=&quot;2&quot;&gt;Evidence Grade&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Definition&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;***&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Strong&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The conclusion is supported by at least two independent studies with high quality, or a good systematic review&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;**&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Moderate&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The conclusion is supported by one study with high quality, and at least two studies with medium quality&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;*&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Limited&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The conclusion is corroborated by at least two studies with medium quality&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; colspan=&quot;2&quot;&gt;Insufficient&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;No conclusions can be drawn when there are no studies that meet the criteria for quality&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; colspan=&quot;2&quot;&gt;Contradictory&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;No conclusions can be drawn when there are studies of the same quality whose finding contradict one another&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review with Evidence Tables" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Critical Appraisal of Papers&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Scientific Secretary ordered full papers and sent them to paired members of the Research Working Group for independent double-blind critical appraisal and grading of the strength of the evidence depending on the likelihood of bias and confounding. Studies were graded according to the revised Scottish Intercollegiate Guidelines Network (SIGN) grading system (2000). The Scientific Secretary informed reviewers of their paired reviewer and shared the results of the independent critical appraisal. Where reviewers disagreed about the score of the paper or its relevance, they discussed it to reach resolution. Where resolution was not achieved, a third reviewer was involved.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Case reports and narrative reviews were excluded. Other reasons to reject studies included:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Papers did not address the scoping questions for this project &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Duplicate publication &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Papers were superseded by more recent studies that incorporated the same data &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Studies based on the same cohort &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Studies did not control for bias or confounding &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Constructing the Evidence Tables&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Scientific Secretary entered the scores and summaries for accepted papers provided by the reviewers into evidence tables. These tables were reviewed in order to formulate evidence statements and recommendations.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Evidence Statements&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The evidence tables were reviewed to formulate evidence statements. An explicit link was made to the most comprehensive and most recent source supporting the evidence for each evidence statement. Where possible this was to a systematic review, which included all earlier original studies in that area. Direct reference to original studies was made where there was no systematic review, where they were not included in the original review(s), or where they were necessary to support an important point.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Criteria for grading evidence and recommendations commonly regard randomised controlled trials as providing the highest level of evidence. However, such hierarchies are designed principally to guide inferences about the effects of treatment. Since randomised controlled trials do not apply in many areas of occupational medicine, e.g., health surveillance, susceptibility to disease or the sensitivity and specificity of screening and diagnostic procedures, there is scarce level 1 evidence as defined by the SIGN grading system. To overcome this limitation the Research Working Group graded the strength of each evidence statement using both the SIGN system and the Royal College of General Practitioners (RCGP) 3 star system modified in 2008 by the Swedish Council on Technology Assessment in Health Care report for scientific studies (see the &quot;Rating Scheme for the Strength of the Evidence&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Stakeholder Involvement&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Members of the 2004 Research Working Group represented key stakeholder groups, including respiratory medicine, general practice, occupational health, patients, employers and workers at risk. The wide stakeholder group was not involved in the more confined task of updating of the evidence for the 2010 guidelines.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Key Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The evidence statements were reviewed to determine key recommendations which were written in precise, behaviourally specific terms. Each recommendation was graded using both the revised Scottish Intercollegiate Guidelines Network (SIGN) grading system (see the &quot;Rating Scheme for the Strength of the Recommendation&quot; field) and the modified Royal College of General Practitioners (RCGP) 3 star system and linked to the supporting evidence statements. As with National Institute for Health and Clinical Excellence (NICE) guidelines, papers with a 'minus' grade (indicating a high level of bias or confounding) or grade 3 or 4 were only used as a basis for a recommendation where there was a lack of stronger evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good Practice Points&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The guidelines include good practice points where there is no, and nor is there likely to be, research evidence. They are based on the clinical experience of the research-working group, legal requirement or other consensus.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Scottish Intercollegiate Guidelines Network (SIGN) Grades of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Scottish Intercollegiate Guidelines Network (SIGN) Grades of Recommendation&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th width=&quot;3%&quot; class=&quot;Center&quot; valign=&quot;top&quot;&gt;A&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;At least one meta analysis, systematic review, or randomised controlled trial rated as 1++, and directly applicable to the target population; or a systematic review of randomised controlled trials or a body of evidence consisting principally of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of results&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;B&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A body of evidence including studies rated as 2++, directly applicable to the target population, and demonstrating overall consistency of results; or extrapolated evidence from studies rated as 1++ or 1+&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;C&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A body of evidence including studies rated as 2+, directly applicable to the target population and demonstrating overall consistency of results; or extrapolated evidence from studies rated as 2++&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;D&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence level 3 or 4; or extrapolated evidence from studies rated as 2+&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Both the 2004 evidence review and the 2010 evidence review were reviewed independently by external reviewers.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Level of evidence and grade of recommendation definitions are provided at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Key Recommendations for Occupational Health Management&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Employers and Their Health and Safety Personnel Should&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Be aware that the major determinant of risk for the development of occupational asthma is the level of exposure to its causes and should implement programmes to remove or reduce exposure to its causes. &lt;strong&gt;** SIGN B&lt;/strong&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;*** SIGN 2++&lt;/strong&gt; The risk of sensitisation and occupational asthma is increased by higher exposures to many workplace agents.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;** SIGN 2+&lt;/strong&gt; Reducing airborne exposure reduces the incidence of sensitisation and occupational asthma. &lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Be aware that respiratory protective equipment does not completely prevent occupational asthma and ensure that when it is worn, the appropriate type is used and maintained, fit testing is performed and workers understand how to wear, remove and replace it. &lt;strong&gt;* SIGN D&lt;/strong&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;* SIGN 3&lt;/strong&gt; The use of respiratory protective equipment reduces the incidence of, but does not completely prevent, occupational asthma.&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Inform workers about any causes of occupational asthma in the workplace and the need to report any relevant symptoms as soon as they develop. &lt;strong&gt;** SIGN D&lt;/strong&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;** SIGN 2+&lt;/strong&gt; The likelihood of improvement or resolution of symptoms or of preventing deterioration is greater in workers who have shorter duration of symptoms prior to diagnosis.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;** SIGN 2+&lt;/strong&gt; The likelihood of improvement or resolution of symptoms or of preventing deterioration is greater in workers who have relatively normal lung function at the time of diagnosis.&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Provide workers at risk of occupational asthma with health surveillance at least annually and more frequently in the first years of exposure. &lt;strong&gt;** SIGN D&lt;/strong&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;** SIGN 2+&lt;/strong&gt; The likelihood of improvement or resolution of symptoms or of preventing deterioration is greater in workers who have relatively normal lung function at the time of diagnosis.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;** SIGN 2+&lt;/strong&gt; The likelihood of improvement or resolution of symptoms or of preventing deterioration is greater in workers who have shorter duration of symptoms prior to diagnosis.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;* SIGN 3&lt;/strong&gt; Health surveillance can detect occupational asthma at an earlier stage of disease and outcome improved in workers who are included in a health surveillance programme.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;** SIGN 2+&lt;/strong&gt; Sensitisation and occupational asthma are most likely to develop in the first years of exposure for workers exposed to enzymes, complex platinum salts, isocyanates and laboratory animal allergens.&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Health Practitioners Should&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;5&quot;&gt;&#xD;&#xA;    &lt;li&gt;Not use poorly discriminating factors - such as atopy, cigarette smoking or a family or personal history of asthma which may increase individual susceptibility to occupational asthma for some agents - as a reason to exclude individuals from employment. &lt;strong&gt;* SIGN D&lt;/strong&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;* SIGN 3&lt;/strong&gt; The positive predictive values of screening criteria are too poorly discriminating for screening out potentially susceptible individuals, particularly in the case of atopy where the trait is highly prevalent.&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Enquire about pre-existing occupational asthma to agents that job candidates might be exposed to in their new job and advise affected candidates that they should not undertake this work, if exposure cannot be adequately controlled. &lt;strong&gt;** SIGN C&lt;/strong&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;** SIGN 2+&lt;/strong&gt; The likelihood of improvement or resolution of symptoms or of preventing deterioration is greater in workers who have little or no further exposure to the causative agent.&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Provide more frequent health surveillance to workers who develop rhinitis when working with agents known to cause occupational asthma and ensure that the workplace and working practices are investigated to identify potential causes and implement corrective actions. &lt;strong&gt;** SIGN D&lt;/strong&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;** SIGN 2+&lt;/strong&gt; Occupational rhinitis and occupational asthma frequently occur as co-morbid conditions.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;** SIGN 2+&lt;/strong&gt; Rhinoconjunctivitis is more likely to appear before the onset of immunoglobulin E (IgE) associated occupational asthma. &lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;*** SIGN 2++&lt;/strong&gt; The risk of developing occupational asthma is highest in the year after the onset of occupational rhinitis.&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Enquire of any adult patient with new, recurrent or deteriorating symptoms of rhinitis or asthma about their job, the materials with which they work and whether their symptoms improve regularly when away from work. &lt;strong&gt;*** SIGN A&lt;/strong&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;*** SIGN 1++&lt;/strong&gt; Occupational factors are estimated to account for about 1 in 6 cases of asthma in adults of working age, including new onset or recurrent disease.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;*** SIGN 2++&lt;/strong&gt; The workers most commonly reported to surveillance schemes of occupational asthma include animal handlers, bakers and pastry makers, chemical workers, food processing workers, hairdressers, paint sprayers, nurses and other health professionals, timber workers and welders.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;** SIGN 2+&lt;/strong&gt; The workers reported from population studies to be at increased risk of developing asthma include bakers, chemical workers, cleaners, cooks, electrical and electronic production workers, farm workers, food processors, forestry workers, healthcare workers, laboratory technicians, mechanics, metal workers, painters, plastics and rubber workers, storage workers, textile workers, waiters, welders and wood workers.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;*** SIGN 2++&lt;/strong&gt; The most frequently reported agents include isocyanates, flour and grain dust, colophony and fluxes, latex, animals, aldehydes and wood dust.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;** SIGN 2+&lt;/strong&gt; In the clinical setting questionnaires that identify symptoms of wheeze and/or shortness of breath which improve on days away from work or on holiday have a high sensitivity, but relatively low specificity for the validation of occupational asthma.&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Confirm a diagnosis of occupational asthma by objective criteria (functional, immunological, or both) and not on the basis of a compatible history alone because of the potential implications for future employment. &lt;strong&gt;** SIGN C&lt;/strong&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;** SIGN 2+&lt;/strong&gt; In the clinical setting questionnaires that identify symptoms of wheeze and/or shortness of breath which improve on days away from work or on holiday have a high sensitivity, but relatively low specificity for the validation of occupational asthma.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;* SIGN 3 &lt;/strong&gt;Free histories taken by experts have high sensitivity, but their specificity may be lower. These values may be affected by differences in language and populations.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;** SIGN 2+ &lt;/strong&gt;Approximately one third of workers with occupational asthma are unemployed up to 6 years after diagnosis.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;** SIGN 2+ &lt;/strong&gt;Workers with occupational asthma suffer financially.&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Arrange for workers who they suspect to have occupational asthma to perform serial peak flow measurements at least four times a day and for at least three weeks. &lt;strong&gt;** SIGN D&lt;/strong&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;** SIGN 3&lt;/strong&gt; In specialist settings acceptable peak flow series can be obtained in around two thirds of those in whom a diagnosis of occupational asthma is being considered.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;* SIGN 3&lt;/strong&gt; The diagnostic performance of serial peak flow measurements falls when fewer than four readings a day are made and records are shorter than three weeks.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;** SIGN 3&lt;/strong&gt; There is high level of agreement between expert interpretations of serial peak flow records.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;** SIGN 3&lt;/strong&gt; Depending on the quality of the recorded series, the sensitivity and specificity of serial peak flow measurements are high in the diagnosis of occupational asthma.&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Employers, Their Health and Safety Personnel and Health Practitioners Should&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;11&quot;&gt;&#xD;&#xA;    &lt;li&gt;Take measures to protect workers diagnosed as having occupational asthma from further exposure to its cause in the workplace. &lt;strong&gt;** SIGN C&lt;/strong&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;** SIGN 2+&lt;/strong&gt; The likelihood of improvement or resolution of symptoms or of preventing deterioration is greater in workers who avoid further exposure to the causative agent.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;** SIGN 2+&lt;/strong&gt; The likelihood of improvement or resolution of symptoms or of preventing deterioration is greater in workers who have shorter duration of symptoms prior to removal from exposure.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;* SIGN 3&lt;/strong&gt; Redeployment to a low exposure area may lead to improvement or resolution of symptoms or prevent deterioration in some workers, but is not always effective.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;** SIGN 2+&lt;/strong&gt; Where clinical considerations permit, reduction of exposure may be a useful alternative associated with fewer socio-economic consequences to complete removal from exposure.&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Good Practice Points for Occupational Health Management&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Health practitioners should assess whether performing skin prick or serological tests as part of the health surveillance of workers exposed to agents that cause IgE associated occupational asthma adds value to assessing the effectiveness of the control of exposure. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Health practitioners should provide more frequent health surveillance to any workers who have pre-existing asthma to detect any evidence of deterioration. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Employers and their health and safety personnel should assess exposure in the workplace and enquire of relevant symptoms among the workforce when any one employee develops confirmed occupational rhinitis or occupational asthma; and identify opportunities to institute remedial measures to protect other workers. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Health practitioners who suspect a worker of having occupational asthma should make an early referral to a physician with expertise in occupational asthma. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Physicians treating patients with occupational asthma should follow published clinical guidelines for the pharmacological management of patients with asthma in conjunction with recommendations to avoid exposure to the causative agent. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Definitions&lt;/strong&gt;&lt;/span&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Scottish Intercollegiate Guidelines Network (SIGN) Levels of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Scottish Intercollegiate Guidelines Network (SIGN) Levels of Evidence&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;1++ &lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High quality meta analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a very low risk of bias&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;1+&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Well conducted meta analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a low risk of bias&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;1-&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Meta analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a high risk of bias&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;2++&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High quality systematic reviews of case-control or cohort studies. High quality case-control or cohort studies with a very low risk of confounding, bias, or chance and a high probability that the relationship is causal&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;2+&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Well conducted case control or cohort studies with a low risk of confounding, bias, or chance and a moderate probability that the relationship is causal&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;2-&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Case control or cohort studies with a high risk of confounding, bias, or chance and a significant risk that the relationship is not causal&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;3&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Non-analytic studies, e.g., case reports, case series&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;4&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Expert opinion&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Royal College of General Practitioners (RCGP) 3 Star System&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;(High quality scientific studies were taken to be major epidemiological surveys and prospective cohort studies. Medium quality studies included retrospective, cross-sectional or uncontrolled cohort studies and case series.)&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Scottish Royal College of General Practitioners (RCGP) 3 Star System&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; colspan=&quot;2&quot;&gt;Evidence Grade&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Definition&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;***&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Strong&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The conclusion is supported by at least two independent studies with high quality, or a good systematic review&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;**&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Moderate&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The conclusion is supported by one study with high quality, and at least two studies with medium quality&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;*&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Limited&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The conclusion is corroborated by at least two studies with medium quality&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; colspan=&quot;2&quot;&gt;Insufficient&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;No conclusions can be drawn when there are no studies that meet the criteria for quality&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; colspan=&quot;2&quot;&gt;Contradictory&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;No conclusions can be drawn when there are studies of the same quality whose finding contradict one another&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Scottish Intercollegiate Guidelines Network (SIGN) Grades of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Scottish Intercollegiate Guidelines Network (SIGN) Grades of Recommendation&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th width=&quot;3%&quot; class=&quot;Center&quot; valign=&quot;top&quot;&gt;A&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;At least one meta analysis, systematic review, or randomised controlled trial rated as 1++, and directly applicable to the target population; or a systematic review of randomised controlled trials or a body of evidence consisting principally of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of results&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;B&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A body of evidence including studies rated as 2++, directly applicable to the target population, and demonstrating overall consistency of results; or extrapolated evidence from studies rated as 1++ or 1+&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;C&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A body of evidence including studies rated as 2+, directly applicable to the target population and demonstrating overall consistency of results; or extrapolated evidence from studies rated as 2++&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;D&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence level 3 or 4; or extrapolated evidence from studies rated as 2+&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good Practice Points&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The guidelines include good practice points where there is no, and nor is there likely to be, research evidence. They are based on the clinical experience of the research-working group, legal requirement or other consensus.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An algorithm for work-related asthma and rhinitis: case finding &amp;amp; management in primary care is available from the British Occupational Health Research Foundation Web site (see the &quot;Availability of Companion Documents&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Improved prevention and reduced incidence of occupational asthma &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reduced severity of cases of the disease by earlier identification and better treatment &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Clinicians, employers and workers need to exercise their judgement, knowledge and expertise when deciding whether it is appropriate to apply guidelines, taking into account individual circumstances and patients' wishes. Clinical judgement is necessary when using evidence statements to guide decision-making. Limited recommendations on a particular issue or effect do not necessarily mean that it is untrue or unimportant but may simply reflect insufficient evidence. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is not intended, nor should it be taken to imply, that these guidelines override existing legal obligations. Duties under the UK Health and Safety at Work Act 1974, the Management of Health and Safety at Work Regulations 1999, the Control of Substances Hazardous to Health Regulations 2002, the Disability Discrimination Act 1995 and 2005 and other relevant legislation and guidance must be given due consideration, as should laws relevant to other countries. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Clinical Algorithm" /><FieldValue Value="Patient Resources" /><FieldValue Value="Quick Reference Guides/Physician Guides" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Living with Illness" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Nicholson PJ, Cullinan P, Burge PS, Boyle C. Occupational asthma: prevention, identification &amp; management: systematic review &amp; recommendations. London (UK): British Occupational Health Research Foundation; 2010. 83 p.  [282 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2004 (revised 2010)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="British Occupational Health Research Foundation - Nonprofit Organization" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;British Occupational Health Research Foundation&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Guideline Development Group&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Guideline Development Group Members&lt;/em&gt;: Dr P J Nicholson (&lt;em&gt;Chairman),&lt;/em&gt; Faculty of Occupational Medicine/Society of Occupational Medicine; Mrs C Boyle (&lt;em&gt;Scientific Secretary&lt;/em&gt;), Health &amp;amp; Safety Executive Professor P S Burge, Birmingham Heartlands Hospital/Birmingham University; Professor P Cullinan, National Heart &amp;amp; Lung Institute/Royal Brompton Hospital&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Professor Sherwood Burge co-developed OASYS, a computer based system to analyse&#xA;serial peak expiratory flow measurements.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: British Occupational Health Research Foundation (BOHRF). Guidelines for the prevention, identification and management of occupational asthma: evidence review and recommendations. London (UK): British Occupational Health Research Foundation (BOHRF); 2004. 88 p.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.bohrf.org.uk/downloads/OccupationalAsthmaEvidenceReview-Mar2010.pdf&quot; title=&quot;British Occupational Health Research Foundation (BOHRF) Web Site&quot;&gt;British Occupational Health Research Foundation (BOHRF) Web Site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Occupational asthma: a guide for occupational health professionals, safety professionals and safety representatives. London (UK): British Occupational Health Research Foundation; 2010 Mar. 6 p. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.bohrf.org.uk/downloads/OA_Guide-1.pdf&quot; title=&quot;British Occupational Health Research Foundation (BOHRF) Web site&quot;&gt;British Occupational Health Research Foundation (BOHRF) Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Occupational asthma: a guide for general practitioners and practice nurses. London (UK): British Occupational Health Research Foundation; 2010 Mar. 6 p. Electronic copies: Available in PDF from the &lt;a href=&quot;http://www.bohrf.org.uk/downloads/OA_Guide-3.pdf&quot; title=&quot;British Occupational Health Research Foundation (BOHRF) Web site&quot;&gt;BOHRF Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Work-related asthma &amp;amp; rhinitis: case finding &amp;amp; management in primary care. London (UK): British Occupational Health Research Foundation; 2010 Mar. 1 p. Electronic copies: Available in PDF from the &lt;a href=&quot;http://www.bohrf.org.uk/downloads/asthmalg2.pdf&quot; title=&quot;British Occupational Health Research Foundation (BOHRF) Web site&quot;&gt;BOHRF Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Occupational asthma: a guide for employers, workers and their representatives. London (UK): British Occupational Health Research Foundation; 2010 Mar. 9 p. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.bohrf.org.uk/downloads/OA_Guide-2.pdf&quot; title=&quot;British Occupational Health Research Foundation (BOHRF) Web site&quot;&gt;British Occupational Health Research Foundation Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p class=&quot;Disclaimer&quot;&gt;Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI on November 4, 2004. The information was verified by the guideline developer on November 10, 2004. This NGC summary was updated by ECRI Institute on July 25, 2012. The updated information was verified by the guideline developer on August 20, 2012.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
